JPWO2021076564A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021076564A5 JPWO2021076564A5 JP2022522657A JP2022522657A JPWO2021076564A5 JP WO2021076564 A5 JPWO2021076564 A5 JP WO2021076564A5 JP 2022522657 A JP2022522657 A JP 2022522657A JP 2022522657 A JP2022522657 A JP 2022522657A JP WO2021076564 A5 JPWO2021076564 A5 JP WO2021076564A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- cdr2
- cdr3
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915123P | 2019-10-15 | 2019-10-15 | |
| US62/915,123 | 2019-10-15 | ||
| PCT/US2020/055497 WO2021076564A1 (en) | 2019-10-15 | 2020-10-14 | Proteins binding nkg2d, cd16 and flt3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551969A JP2022551969A (ja) | 2022-12-14 |
| JPWO2021076564A5 true JPWO2021076564A5 (es) | 2023-10-19 |
Family
ID=75538862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522657A Pending JP2022551969A (ja) | 2019-10-15 | 2020-10-14 | Ｎｋｇ２ｄ、ｃｄ１６およびｆｌｔ３に結合するタンパク質 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240117054A1 (es) |
| EP (1) | EP4045538A1 (es) |
| JP (1) | JP2022551969A (es) |
| KR (1) | KR20220083770A (es) |
| CN (1) | CN115298217A (es) |
| AR (1) | AR120223A1 (es) |
| AU (1) | AU2020368163A1 (es) |
| BR (1) | BR112022007128A2 (es) |
| CA (1) | CA3153858A1 (es) |
| CL (1) | CL2022000928A1 (es) |
| CO (1) | CO2022004757A2 (es) |
| IL (1) | IL292261A (es) |
| MX (1) | MX2022004430A (es) |
| PE (1) | PE20221316A1 (es) |
| TW (1) | TW202128759A (es) |
| WO (1) | WO2021076564A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019157366A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| AU2022333099A1 (en) * | 2021-08-24 | 2024-02-08 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and uses thereof |
| AU2022358500A1 (en) * | 2021-09-29 | 2024-04-04 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and baff-r |
| WO2023107956A1 (en) * | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024102693A2 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Il-18-fc fusion proteins |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| CA2992539A1 (en) * | 2015-07-16 | 2017-01-19 | Cellerant Therapeutics, Inc. | Cysteine-substituted immunoglobulins |
| BR112020001972A2 (pt) * | 2017-07-31 | 2020-08-04 | Dragonfly Therapeutics, Inc. | proteínas de ligação a nkg2d, cd16 e flt3 |
-
2020
- 2020-10-14 BR BR112022007128A patent/BR112022007128A2/pt unknown
- 2020-10-14 AU AU2020368163A patent/AU2020368163A1/en active Pending
- 2020-10-14 AR ARP200102840A patent/AR120223A1/es unknown
- 2020-10-14 EP EP20876627.9A patent/EP4045538A1/en active Pending
- 2020-10-14 US US17/769,160 patent/US20240117054A1/en active Pending
- 2020-10-14 CA CA3153858A patent/CA3153858A1/en active Pending
- 2020-10-14 CN CN202080072319.9A patent/CN115298217A/zh active Pending
- 2020-10-14 MX MX2022004430A patent/MX2022004430A/es unknown
- 2020-10-14 JP JP2022522657A patent/JP2022551969A/ja active Pending
- 2020-10-14 PE PE2022000621A patent/PE20221316A1/es unknown
- 2020-10-14 TW TW109135528A patent/TW202128759A/zh unknown
- 2020-10-14 WO PCT/US2020/055497 patent/WO2021076564A1/en unknown
- 2020-10-14 KR KR1020227016160A patent/KR20220083770A/ko unknown
-
2022
- 2022-04-12 CL CL2022000928A patent/CL2022000928A1/es unknown
- 2022-04-13 IL IL292261A patent/IL292261A/en unknown
- 2022-04-13 CO CONC2022/0004757A patent/CO2022004757A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brinkmann et al. | The making of bispecific antibodies | |
| JP2021098732A5 (es) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021098733A5 (es) | ||
| US8796424B2 (en) | Tri- or tetraspecific antibodies | |
| IL261674A (en) | Protein-like binding proteins with a double variable region have a cross-linking region direction | |
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2018537966A5 (es) | ||
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| TW201540728A (zh) | 多重特異性抗體 | |
| MX2011010159A (es) | Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla. | |
| JP2023052214A5 (es) | ||
| WO2010112194A1 (en) | Antigen-binding polypeptides and multispecific antibodies comprising them | |
| JP2023106433A5 (es) | ||
| JP2021507698A5 (es) | ||
| Spasevska | An outlook on bispecific antibodies: Methods of production and therapeutic benefits | |
| JPWO2020033702A5 (es) | ||
| JPWO2022102768A5 (es) | ||
| JPWO2019157366A5 (es) | ||
| JPWO2021076564A5 (es) | ||
| JPWO2021064137A5 (es) | ||
| JPWO2020033587A5 (es) | ||
| IL311617A (en) | NKG2D, CD16 and BAFF-R binding proteins | |
| CA3207821A1 (en) | Orthogonal mutations for heterodimerization | |
| Ko et al. | Engineering antibodies for dual specificity and enhanced potency |